Abstract:The recently discovered long noncoding RNAs have the potential to regulate many biological processes, which are aberrantly expressed in many tumor types. Our previous study showed that the long noncoding RNA-growth arrest-specific transcript 5 (GAS5) was decreased in lung cancer tissue, which contributed to the proliferation and apoptosis of nonsmall cell lung cancer (NSCLC). GAS5 was also associated with the prognosis of lung cancer patients. These results suggest that GAS5 may represent a novel prognostic indicator and a target for gene therapy in NSCLC. However, the expression and diagnosis significance of GAS5 in the plasma of NSCLC patients was unknown. The plasma samples were more readily available than the tissue samples in clinical, so we designed the study to investigate the diagnosis value of GAS5 in blood samples. In our study, 90 patients with NSCLC and 33 healthy controls were included. Blood samples were collected before surgery and therapy. We extracted the free RNA in the plasma and analyzed the expression of GAS5 with quantitative reverse transcription PCR. Suitable statistics methods were used to compare the plasma GAS5 levels of preoperative and postoperative plasma samples between the NSCLC patients and healthy controls. Receiver-operating characteristic curve analysis was used to evaluate the diagnostic sensitivity and specificity of plasma GAS5 in NSCLC. The results showed that GAS5 was detectable and stable in the plasma of NSCLC patients. Furthermore, the plasma levels of GAS5 were significantly down-regulated in NSCLC patients compared with healthy controls (P=0.000). Moreover, GAS5 levels increased markedly on the seventh day after surgery compared with preoperative GAS5 levels in NSCLC patients (P=0.003). GAS5 expression levels could be used to distinguish NSCLC patients from control patients with an area under the curve of 0.832 (P<0.0001; sensitivity, 82.2%; specificity, 72.7%). The combination of the GAS5 and carcinoembryonic antigen could produce an area of 0.909 under the receiver-operating characteristic curve in distinguishing NSCLC patients from control subjects (95% confidence interval 0.857-0.962, P=0.000). We have demonstrated that GAS5 expression was decreased in NSCLC Plasma. Plasma samples were more accessible than tissue samples in clinical; therefore, GAS5 could be an ideal biomarker for the diagnosis of NSCLC.

Systematic Review and Meta-Analysis of the Utility of Long Non-Coding RNA GAS5 As a Diagnostic and Prognostic Cancer Biomarker.

Long Noncoding RNA GAS5 Can Predict Metastasis and Poor Prognosis: a Meta-Analysis.

The role of long non-coding RNA GAS5 in cancers

A Critical Role for the Long Non‐coding RNA GAS5 in Proliferation and Apoptosis in Non‐small‐cell Lung Cancer

Gain of GAS5 Reveals Worse Prognosis in Kidney Renal Clear Cell Carcinoma and Liver Hepatocellular Carcinoma from the Cancer Genome Atlas Dataset.

Long non-coding RNA GAS5 in human cancer

Long Non‑coding RNA GAS5 in Human Cancer (Review)

Circulating Long Non-Coding RNA GAS5 Is a Novel Biomarkers for the Diagnosis of Non-Small Cell Lung Cancer

Decreased Expression of Long Non-Coding Rna Gas5 Promotes Cell Proliferation, Migration and Invasion, and Indicates A Poor Prognosis in Ovarian Cancer

Identification Of Circulating Long Non-Coding Rna Gas5 As A Potential Biomarker For Non-Small Cell Lung Cancer Diagnosis

Long Noncoding RNA GAS5 Affects Cell Proliferation and Predicts a Poor Prognosis in Patients with Colorectal Cancer

The growth arrest-specific transcript 5 (GAS5): a pivotal tumor suppressor long noncoding RNA in human cancers

Down-regulation of Long Non-Coding RNA GAS5-AS1 and Its Prognostic and Diagnostic Significance in Hepatocellular Carcinoma

Decreased Expression of Long Noncoding Rna Gas5 Indicates A Poor Prognosis and Promotes Cell Proliferation in Gastric Cancer

Long Non-Coding RNA GAS5 Inhibits Cell Proliferation, Induces G0/G1 Arrest and Apoptosis, and Functions As a Prognostic Marker in Colorectal Cancer.

Decreased expression of long non-coding RNA GAS5 indicates a poor prognosis and promotes cell proliferation and invasion in hepatocellular carcinoma by regulating vimentin.

Upregulation of Long Noncoding RNA_GAS5 Suppresses Cell Proliferation and Metastasis in Laryngeal Cancer via Regulating PI3K/AKT/mTOR Signaling Pathway

Tumor‐derived exosomal lncRNA GAS5 as a biomarker for early‐stage non‐small‐cell lung cancer diagnosis

Circulating long noncoding RNA GAS5 as a potential biomarker in breast cancer for assessing the surgical effects

Long Noncoding RNA GAS5 Acts As A Tumor Suppressor in Laryngeal Squamous Cell Carcinoma Via Mir-21.

The prognostic significance of lncRNA FGD5-AS1 in various malignancies: a meta-analysis